The Diabetic Neuropathy Treatment Market is Predict to reach USD 7.4 Billion by 2031, at a CAGR of 7.3%

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Diabetic Neuropathy Treatment Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Diabetic Neuropathy Treatment Market size is expected to reach $7.4 billion by 2031, rising at a market growth of 7.3% CAGR during the forecast period.

The Retail Pharmacies segment is anticipating a CAGR of 7.7% during (2024 - 2031). Retail pharmacies offer a wide range of medications for diabetic neuropathy, including pain relievers, antidepressants, anticonvulsants, and other medications commonly used to manage symptoms of the condition. These pharmacies also provide over-the-counter medications and supplies that can be helpful for individuals with diabetic neuropathy, such as foot care products and vitamins.

Diabetic Neuropathy Treatment Market Size - By Region

The Non-Steroidal Anti-inflammatory Drugs (NSAIDs) segment is leading the Global Diabetic Neuropathy Treatment Market by Drug Class in 2023; thereby, achieving a market value of $2.8 billion by 2031. NSAIDs include a range of medications, both prescription and over the counter, used to relieve pain and inflammation associated with diabetic neuropathy. Common NSAIDs include ibuprofen, naproxen, and aspirin. NSAIDs function by impeding the synthesis of prostaglandins, which are endogenous lipid compounds implicated in the pathogenesis of inflammation and pain.

The Proximal Neuropathy segment is registering a CAGR of 8.7% during (2024 - 2031). Diabetic proximal neuropathy, alternatively referred to as diabetic amyotrophy or diabetic lumbosacral radiculoplexus neuropathy, impacts the nerve supply to the legs, hips, thighs, or buttocks. It is characterized by severe pain, weakness, and muscle atrophy, often on one side of the body. The demand for proximal neuropathy treatments is driven by the need for effective therapies to manage the debilitating symptoms of this condition.

Full Report: https://www.kbvresearch.com/diabetic-neuropathy-treatment-market/

The North America region dominated the Global Diabetic Neuropathy Treatment Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $2.8 billion by 2031. The Europe region is experiencing a CAGR of 6.9% during (2024 - 2031). Additionally, The Asia Pacific region would exhibit a CAGR of 8.2% during (2024 - 2031).

List of Key Companies Profiled

Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Others

By Drug Class

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Antidepressants
Opioid
Capsaicin
Others

By Disorder Type

Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Related Reports:

SUBSCRIPTION MODEL

The Diabetic Neuropathy Treatment Market is Predict to reach USD 7.4 Billion by 2031, at a CAGR of 7.3%

Special Offering :

Diabetic Neuropathy Treatment Market Growth, Trends and Report Highlights

List of Key Companies Profiled

Diabetic Neuropathy Treatment Market Report Segmentation

North America Diabetic Neuropathy Treatment Market Size 2031

LAMEA Diabetic Neuropathy Treatment Market Size Trend 2031

Europe Diabetic Neuropathy Treatment Market Size to 2031

Asia Pacific Diabetic Neuropathy Treatment Market Size 2031